Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection.

Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, Flynn JL, Fortune SM.

Nat Genet. 2011 May;43(5):482-6. doi: 10.1038/ng.811. Epub 2011 Apr 24.

2.

Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC.

Am J Respir Crit Care Med. 2011 Jul 15;184(2):269-76. doi: 10.1164/rccm.201011-1924OC. Epub 2011 Apr 21.

3.

Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.

Drusano GL, Vanscoy B, Liu W, Fikes S, Brown D, Louie A.

Antimicrob Agents Chemother. 2011 Jun;55(6):2693-5. doi: 10.1128/AAC.01687-10. Epub 2011 Mar 21.

4.

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US.

Br J Clin Pharmacol. 2011 Jul;72(1):51-62. doi: 10.1111/j.1365-2125.2011.03940.x.

5.

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Pasipanodya J, Gumbo T.

Antimicrob Agents Chemother. 2011 Jan;55(1):24-34. doi: 10.1128/AAC.00749-10. Epub 2010 Oct 11. Review.

6.

Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.

Drusano GL, Fregeau C, Liu W, Brown DL, Louie A.

Antimicrob Agents Chemother. 2010 Oct;54(10):4368-72. doi: 10.1128/AAC.00133-10. Epub 2010 Jun 1.

7.

Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2010 Jul;54(7):2847-54. doi: 10.1128/AAC.01567-09. Epub 2010 May 3.

8.

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T.

J Infect Dis. 2010 Apr 15;201(8):1225-31. doi: 10.1086/651377.

9.

Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.

Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JH, Karakousis PC.

J Infect Dis. 2009 Oct 1;200(7):1136-43. doi: 10.1086/605605.

PMID:
19686043
10.

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Gumbo T, Dona CS, Meek C, Leff R.

Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204. doi: 10.1128/AAC.01681-08. Epub 2009 May 18.

11.

Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.

Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW.

Antimicrob Agents Chemother. 2009 Jul;53(7):2974-81. doi: 10.1128/AAC.01520-08. Epub 2009 Apr 20.

12.

Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P.

Clin Infect Dis. 2009 Jan 15;48(2):179-85. doi: 10.1086/595689.

13.

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US.

Antimicrob Agents Chemother. 2008 Jun;52(6):2138-48. doi: 10.1128/AAC.00461-07. Epub 2008 Apr 7.

14.

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.

Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J.

Antimicrob Agents Chemother. 2007 Dec;51(12):4261-6. Epub 2007 Oct 15.

15.

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL.

Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8. Epub 2007 Aug 27.

16.

Isoniazid activity is terminated by bacterial persistence.

Mitchison DA, Jindani A, Davies GR, Sirgel F.

J Infect Dis. 2007 Jun 15;195(12):1871-2; author reply 1872-3. No abstract available.

PMID:
17492605
17.

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.

Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL.

Antimicrob Agents Chemother. 2007 Jul;51(7):2329-36. Epub 2007 Apr 16.

18.

Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.

Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL.

J Infect Dis. 2007 Jan 15;195(2):194-201. Epub 2006 Dec 7.

PMID:
17191164
19.

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US.

Eur J Clin Pharmacol. 2006 Sep;62(9):727-35. Epub 2006 May 10. Erratum in: Eur J Clin Pharmacol. 2006 Sep;62(9):779.

PMID:
16685561
20.

Identification of Nudix hydrolase family members with an antimutator role in Mycobacterium tuberculosis and Mycobacterium smegmatis.

Dos Vultos T, Blázquez J, Rauzier J, Matic I, Gicquel B.

J Bacteriol. 2006 Apr;188(8):3159-61.

Supplemental Content

Support Center